BiotechTube
60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals

SXTP
Washington, United States
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

SXTP · Stock Price

USD 1.58-8.10 (-83.68%)
Market Cap: $4.1M

Historical price data

Overview

60 Degrees Pharmaceuticals is a U.S.-based public biotech company (NASDAQ: SXTP) with a mission to develop and commercialize treatments for infectious diseases, particularly in the underserved tropical disease market. Its core achievement is the FDA approval and commercialization of ARAKODA® (tafenoquine) for malaria prophylaxis in adults, a product distinguished by its convenient weekly dosing. The company's strategy centers on the strategic repurposing and lifecycle management of tafenoquine for additional anti-infective indications while navigating the complex commercial and funding landscape of a micro-cap tropical disease biotech.

Infectious DiseaseTropical Disease

Technology Platform

A strategic platform focused on the repurposing and lifecycle management of the 8-aminoquinoline compound tafenoquine for multiple infectious disease indications, leveraging its established safety profile to de-risk and accelerate development.

Opportunities

The major near-term opportunity is the successful Phase 3 development and regulatory approval of tafenoquine for the radical cure of P.
vivax malaria, which addresses a massive global health need and a significantly larger market than prophylaxis.
Success here could attract strategic partnerships with global health organizations and drive substantial value creation.

Risk Factors

The company faces extreme single-asset concentration risk, where its viability depends entirely on tafenoquine.
It also contends with severe financial and liquidity risk as a micro-cap stock, making consistent funding a persistent challenge that could hinder its ability to reach critical milestones.

Competitive Landscape

In prophylaxis, ARAKODA® competes against daily-dosed generics (atovaquone/proguanil, doxycycline) and the weekly but side-effect-prone mefloquine. In the target radical cure market, its primary competitor is generic primaquine, though it also faces competition from GSK's WHO-prequalified pediatric tafenoquine (Kozenis®).

More companies in United States →